MABT1551

Anti-Filaggrin Antibody, clone AHF7

• Synonim(y): FLG
• Kod UNSPSC: 12352203
• NACRES: NA.43

Właściwości

• pochodzenie biologiczne: mouse
• Poziom jakości: 200
• forma przeciwciała: purified antibody
• rodzaj przeciwciała: primary antibodies
• klon: AHF7, monoclonal
• masa cząsteczkowa: observed mol wt ~N/A kDa
• oczyszczone przez: ion-exchange chromatography
• reaktywność gatunkowa: human
• opakowanie: antibody small pack of 100
• metody: ELISA: suitable; electron microscopy: suitable; immunofluorescence: suitable; immunohistochemistry: suitable; western blot: suitable
• izotyp: IgG1κ
• sekwencja epitopowa: Unknown
• numer dostępu Protein ID: NP_002007
• numer dostępu UniProt: P20930
• temp. przechowywania: -10 to -25°C
• informacje o genach: human ... FLG(2312)

Opis

Specyficzność

Clone AHF7 is a mouse monoclonal antibody that detects the mature form of Filaggrin.

Immunogen

Partially purified Filaggrin from human breast skin tissue.

Zastosowanie

Quality Control Testing

Evaluated by Immunohistochemistry (Paraffin) in Human skin tissue sections.

Immunohistochemistry (Paraffin) Analysis: A 1:50 dilution of this antibody detected Filaggrin in Human skin tissue sections.

Tested Applications

Immunohistochemistry Applications: A representative lot detected Filaggrin in Immunohistochemistry application. (Simon, M., et al. (1995). Clin Exp Immunol. 100(1):90-8; Simon, M., et al. (1995). J Invest Dermatol. 105(3):432-7; Girbal-Neuhauser, E., et al. (1997). Mol Med. 3(2):145-56; Guy, R., et al. (1998). Dermatology. 196(1):32-7; Guy, R., et al. (1998). J Invest Dermatol. 110(4):410-5; Downie, M.M.T., et al. (2002). Br J Dermatol. 147(5):869-78; Chavanas, S., et al. (2006). J Dermatol Sci. 44(2):63-72).

Immunofluorescence Analysis: A representative lot detected Filaggrin in Immunfluorescence application. (Simon, M., et al. (1995). Clin Exp Immunol. 100(1):90-8; Simon, M., et al. (1995). J Invest Dermatol. 105(3):432-7; Girbal-Neuhauser, E., et al. (1997). Mol Med. 3(2):145-56; Chavanas, S., et al. (2006). J Dermatol Sci. 44(2):63-72).

ELISA Analysis: A representative lot detected Filaggrin in ELISA application. (Simon, M., et al. (1996). Biochem J. 317(Pt1)(Pt1):173-7).

Electron Microscopy: A representative lot detected Filaggrin in Electron Microscopy application. (Simon, M., et al. (1995). J Invest Dermatol. 105(3):432-7).

Western Blotting Analysis: A representative lot detected Filaggrin in Western Blotting application. (Sebbag, M., et al. (1995). J Clin Invest. 95(6):2672-9; Simon, M., et al. (1995). J Invest Dermatol. 105(3):432-7; Simon, M., et al. (1996). Biochem J. 317(Pt1)(Pt1):173-7; Girbal-Neuhauser, E., et al. (1997). Mol Med. 3(2):145-56).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Opis wartości docelowych

Filaggrin (UniProt: P20930; also known as FLG) is encoded by the FLG gene (Gene ID: 2312) in human. Filaggrin, a calcium-binding protein, is synthesized as a large, insoluble, highly phosphorylated precursor with several tandem copies of 324 amino acids in cytoplasmic granules. During terminal differentiation it undergoes dephosphorylation and proteolytic cleavage to remove linker peptides and produce functional basic filaggrin units. It is widely expressed and in skin tissue it is detected mainly in stratum granulosum of the epidermis. During terminal differentiation of mammalian epidermis, it aggregates keratin intermediate filaments and promotes disulfide-bond formation among the intermediate filaments. This creates the intracellular fibrous matrix of the cornified cells. Deimination of arginine to citrulline by peptidylarginine deiminase is reported to result in reduction in its affinity for cytokeratins. The N-terminal region of the mature filaggrin is shown to be heterogenous and is blocked by the formation of pyroglutamate. Clone AHF7 detects only the mature form of filaggrin and does not detect profilaggrin. It exhibits reactivity in various immunochemical applications. (Ref.: Simon, M., et al. (1996). Biochem. J. 317(pt 1); 173 177; Simon, M., et al. (1995). Clin. Exp. Immunol. 100(1); 90-98; Simon, M., et al. (1995). J. Invest. Dermatol. 105(3); 432-437).

Postać fizyczna

Purified mouse monoclonal antibody IgG1 in buffer containing PBS with 0.1% sodium azide with 50% glycerol.

Rekonstytucja

0.5 mg/mL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Przechowywanie i stabilność

Store at -10°C to -25°C. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Inne uwagi

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Oświadczenie o zrzeczeniu się odpowiedzialności

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

This page may contain text that has been machine translated.

Informacja o środkach bezpieczeństwa

• Kod klasy składowania: 12 - Non Combustible Liquids
• Klasa zagrożenia wodnego (WGK): WGK 2
• Temperatura zapłonu (°F): Not applicable
• Temperatura zapłonu (°C): Not applicable